story of the week
Amcenestrant vs Standard Endocrine Monotherapy for ER+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
J. Clin. Oncol 2023 Jun 22;[EPub Ahead of Print], SM Tolaney, A Chan, K Petrakova, S Delaloge, M Campone, H Iwata, PF Peddi, PA Kaufman, E De Kermadec, Q Liu, P Cohen, G Paux, L Wang, N Ternès, E Boitier, SA ImFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.